TOP NEWS

March 19, 2026
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
March 02, 2026
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
VIEW ALL

WE ARE SOCIAL